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 Effect of boron on the differentiation of mesenchymal stem cells 
 
Boron is an essential microelement in the metabolism of living organisms. However, its 
role is not well defined yet. It has been shown recently that boron has a positive effect on the 
differentiation on murine myoblasts and some reports describe boron to be involved on bone 
mineralization. For that reasons, it is done in this work a research using different 
concentrations of boron in a material system composed by PLLA (poly lactic-L-acid) as a 
substrate, in order to verify if boron has also an effect on the differentiation of mesenchymal 
stem cells to different lineages (myoblast, osteoblast, adipocyte or for the contrary stemness 
maintenance). With this, it could be favored the regeneration of both damaged muscle tissue 
and bone tissue, achieving in that way an important progress on tissue engineering, adding to 
the current techniques just a microelement, boron. 
Keywords: boron – differentiation – mesenchymal stem cells – PLLA 
 
Efecto del boro en la diferenciación de células madre mesenquimales 
 
El boro es un microelemento esencial en el metabolismo de los seres vivos, aunque su 
papel en este no está bien definido. Se ha demostrado recientemente que el boro tiene un 
efecto positivo en la diferenciación de mioblastos murinos, y algunos estudios describen que el 
boro puede intervenir en la mineralización del hueso. Por ello, se realiza aquí un estudio 
empleando diferentes concentraciones de boro y PLLA (ácido-L-poliláctico) como soporte, con 
el fin de comprobar si el boro tiene también un efecto en la diferenciación de células madre 
mesenquimales hacia varios linajes diferentes (mioblasto, osteoblasto, adipocito o por el 
contrario mantenimiento de las células en su estadío indiferenciado). Se podría con ello 
favorecer la regeneración tanto de tejido muscular como tejido óseo dañado, consiguiendo así 
un avance importante en la ingeniería de tejidos, añadiendo a las técnicas actuales tan solo un 
microelemento, el boro. 
Palabras clave: boro – diferenciación – células madre mesenquimales – PLLA 
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1. Introduction 
1.1. Context: tissue engineering 
 
This project is framed on the relatively new field of Tissue Engineering. This field applies 
the principles of engineering and biology in order to develop biological substitutes that restore, 
maintain or improve tissue function mainly when a tissue has been damaged or an organ has 
failed (Berthiaume, Maguire, and Yarmush 2011; Langer and Vacanti 1993). The strategy followed 
to create a new tissue structure combines three main components: 
a) Living cells: these cells can be obtained either from a donor or from a patient. When 
they are obtained from the patient, they can be mesenchymal stem cells, cells from 
the tissue that wants to be repaired or induced stem cells. 
b) Biocompatible materials: polymers that serve as support and protection for the cells, 
so they provide an environment similar to the extracellular matrix of their native 
tissue.  
c) Biochemical factors: substances and biomolecules that favor the proliferation and/or 
differentiation of the cells. They can be used in vitro to prepare the cells before 
implanting them, or they can be loaded into the biocompatible material to be 
released inside the body. 
These three strategies can be used to create a tissue-like structure with the objective of 
regenerating a damaged tissue or organ. In this project there is a special focus on a biochemical 
factor acting as a bioactive ion: boron. We performed a novel approach to test the effects of 
boron on mesenchymal stem cell differentiation. A biocompatible material, poly-lactic acid, is 
going to be used. This will allow assessing the potential of boron for applications in tissue 
engineering.   
In the following sections they will be developed the main reasons for choosing boron, 
poly-lactic acid and mesenchymal stem cells on this project. 
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1.2. Biochemical factor as bioactive ion: boron (B) 
In tissue engineering the biochemical factors are substances and molecules that improve 
the proliferation and/or differentiation of cells. An objective widely pursued in tissue engineering 
is to favor cell differentiation, in order to obtain cells that will replace the specific damaged tissue. 
Growth factors, signal molecules and microelements are used for this purpose. The factors used 
to differentiate mesenchymal stem cells to either bone, muscle or adipose cells will be detailed in 
section 1.4. The biochemical factors to differentiate each type of cell are selected through a 
process of both trial and error and through analysis of molecules that have shown potential. 
Boron is one of these potential factors, as has been shown in numerous studies.  
 
Boron (B) is a metalloid essential for life as a micronutrient. It is usually found in the Earth 
as boric acid B(OH)3 and in a lesser extent as borate B(OH)4
− (Zangi 2012). Its relevance and 
mechanism in plants have been exhaustively described (Blevins and Lukaszewski 1998). In animals 
and humans, it has been shown to be involved in metabolism and homeostasis regulation 
(Pizzorno 2015). However, its mechanism of action is not fully understood yet.  
 
1.2.1. Role of boron in physiology 
After boron was widely accepted as an essential element in plants, researchers have been 
studying its relevance in animals. Boron deficiency has been shown to affect negatively the life 
cycle, with impaired growth, development or maturation. In mammals there is no finding about 
effects of boron in the life cycle, but it has been shown by various studies of boron depletion-
repletion that it is beneficial and probably required for health (Nielsen 2014; Hunt 2012). The 
1996 report of the World Health Organization, "Trace elements in human nutrition and health" 
(World Health Organization 1996), includes boron as a trace element that is probably essential for 
life.  
Boron can be found in human diet in vegetables, fruits, legumes and nuts, ranging from 
0.86 to 2.06 mg in a typical serving of the richest food sources (Pizzorno 2015).  The metalloid is 
highly soluble, so it is absorbed through gastrointestinal epithelia and excreted in urine. The 
concentration of boron in urine is similar to the boron intake, and it has been found that a higher 
B intake does not increase significantly its plasma levels (Nielsen and Penland 1999; Liao et al. 
2011), meaning that there must be a mechanism that regulates efficiently boron homeostasis. It is 
believed that the body has a storage reserve of boron because more than 21 days are necessary 
to see changes in humans fed by a low-boron diet. It is important to take into account that in 
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studies were the boron intake is increased in humans it is possible to see positive changes in the 
patient, meaning that their daily intake was probably lower than the necessary. World Health 
Organization recommends 1mg/day, and settles the safe intake range at 1-13mg/day (WORLD 
HEALTH ORGANIZATION 1996). Since the date of report of the WHO, many studies have 
confirmed the relevance of boron for human health. 
 
It was firstly suggested that boron can enhance and mimic some effects of estrogen 
therapy in post-menopausal women, meaning that an increased intake of boron can alleviate the 
symptoms of post-menopause by preventing calcium loss and bone demineralization. Boron 
achieves this by reducing calcium and magnesium urinary excretion, increasing serum levels of 
17β-estradiol and testosterone (Nielsen, Mullen, and Hunt 1987; Nielsen and Penland 1999). In an 
early study it was shown that plasma calcium and serum 25-hydroxycholecalciferol (indicator of 
vitamin D levels) were lower during boron depletion and serum calcitonin and osteocalcin were 
higher during boron depletion (Nielsen, Mullen, and Gallagher 1990). Due to effect on 
bioavailability of estradiol and vitamin D, boron is said to affect steroid hormone metabolism in 
humans. It can be also concluded that boron has a role on mineral metabolism, due to the 
changes of its effect depending on the concentration of other minerals like magnesium. 
Boron has also been found to reduce levels of inflammatory biomarkers such as high-
sensitivity C-reactive proteins (CRP) and tumor necrosis factor α (TNF-α) (Naghii et al. 2011). This 
is of relevance because high levels of CRP are related to increased risk of cardiovascular disease, 
cancer, obesity and stroke, among other diseases. Other interesting effects of boron in mammals 
reviewed by Pizzorno (2015) are that it raises levels of antioxidant enzymes, protects against 
oxidative stress induced by pesticides and heavy-metal toxicity and improves the cognitive 
performance, as well as the short-term memory in elders. 
 
In studies regarding the action of boron at a molecular rather than physiological level, it 
has been found to regulate the expression of certain proteins. Dzondo-Gadet et al. (2002) showed 
that adding 10mM of boron at cell-free systems increased by 6 fold the RNA synthesis of genes 
coding for proteins involved in angiogenesis (VEGF), wound healing (TGFβ) and growth factors 
(TNFα). They also concluded that boron effect was exerted on a transcriptional level rather than 
translational. In order to have effect in transcription, it is necessary that B enters the cell. In 
aqueous solution B is found as multivalent specie poly-hydroxylated. In this state is hydrophilic 
and medium-sized, reason why it was hypothesized that it passed through the membrane by 
simple diffusion or through an unspecific ion channel (Zangi 2012). In plants there is a boron 
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transporter, AtBor1 (Takano et al. 2002), which has a homologous in mammals, NaBC1. In the 
absence of borate, it transports Na+ and OH- through the cell membrane. In the presence of 
borate, it acts as an electrogenic Na+ coupled borate co-transporter, very specific for borate and 
sensitive even at very low concentrations (Park et al. 2004). Later, it was described how dietary 
supplementation of boron alters expression of NaBC1 mRNA in pigs (Liao et al. 2011). As B is 
absorbed through the gastrointestinal epithelia, the researchers studied the expression of NaBC1 
in cells of this tissue, as well as in kidney, one of the most relevant organs for homeostasis 
regulation. When supplementing the pig’s diet with boron, the expression of NaBC1 mRNA 
increased a 213% in jejunum and decreased a 35% in kidney. This data suggests that both 
intestine and kidney regulate B uptake and excretion. Loss of expression of NaBC1 in kidney 
causes polyuria and an increase in urine of Na, Cl, K and Mg, supporting the theory that states 
that B is implicated in mineral metabolism.  
Silencing of NaBC1 reduces a 50% the incorporation of thymidine in the cell. In their 
research Park et al. (2004) showed that borate at low concentrations has a mitogenic effect by 
activating the MAPK pathway through phosphorylation, increasing in that way cell proliferation 
and growth. The initiation and elongation steps of DNA transcription also require phosphorylation 
(Dzondo-Gadet et al. 2002). These are the reasons why probably silencing of NaBC1 reduced 
incorporation of a molecule relevant in cell proliferation and RNA synthesis.  
Another explanation for the mechanism of action of boron is defined by its biochemistry. 
Boric acid forms complexes with hydroxyl groups in cis orientation. These groups are found mainly 
in sugars as ribose, a component of adenosine. When analyzing by capillary electrophoresis which 
molecules bound strongly to boron, they were found S-adenosylmethionine (SAM) and 
diadenosine phosphates (Ralston and Hunt 2001), both molecules that contain adenosine. Around 
95% of SAM is used in methylation reactions, influencing the activity of DNA, RNA, proteins, 
phospholipids, hormones and neurotransmitters. There is a study in rats that backs the hypothesis 
that part of the boron activity is through SAM formation and/or use (Nielsen 2014). On the other 
hand, boron also binds strongly to the ubiquitous molecule nicotinamide adenine dinucleotide 
(NAD+), giving strength to the relevance of boron in the molecular level. 
 
1.2.2. Drugs and boron 
As seen in the previous section, boron has many functions at the molecular level, which 
are mainly due to its particular chemical structure. B is very similar to carbon –with one electron 
less– meaning that it is a good carbon analog. This characteristic is useful for pharmaceuticals 
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based on enzyme inhibition, particularly of hydrolytic enzymes, due to the change of trigonal to 
tetrahedral form that occurs both in carbon and boron transition state molecules during 
enzymatic hydrolysis (Yang, Gao, and Wang 2003). As reviewed in Baker et al. (2009) other 
enzyme inhibitors containing boron that are being used to treat disease are inhibitors of 
dipeptidyl peptidase 4 (DPP4) and inhibitors of phosphodiesterase 4 (PDE). One DDP4 inhibitor 
containing boron, Januvia®, was approved by the FDA for the treatment of type II diabetes, and 
another one, Talabostat, is in phase III clinical trials to treat non-small cell lung cancer. AN2728 is 
in phase II clinical trials as PDE inhibitor for the treatment of psoriasis. Additionally, other boron 
based serine protease inhibitors are being studied as anticoagulants, as they inhibit thrombin or 
Factor Xia in the blood coagulation cascade. TRI50c is in phase III clinical trials as anticoagulant. 
One particular use of boron containing molecules is for cancer treatment. Among the first 
boron-containing compounds approved for human use are drugs that include a non-radioactive 
isotope of boron-10 for their use in boron neutron-capture therapy (BNCT), to treat brain, head 
and neck tumors (Soloway et al. 1998). Velcade® is a peptidic proteasome inhibitor to treat 
multiple myeloma and non-Hodgkin’s lymphoma, and it was the first boron based therapeutic in 
the market (Adams and Kauffman 2004). Boric acid has shown to have antiprostate cancer effects 
by decreasing serum prostate specific antigen (Gallardo-Williams et al. 2004), decreasing 
expression of A-E cyclin (Barranco et al. 2009) and activating ER-β (estrogen receptor),which has 
an anti-proliferative role (Ohta et al. 2013). One study suggested that boron-rich diets are 
correlated with lower incidence of cervical cancer, possibly through the serine protease inhibition 
of HPV oncogene (Korkmaz et al. 2007). Increased boron intake is correlated with decreasing odds 
of lung cancer with a similar effect compared to hormone replacement therapy, possibly because 
higher boron intake increases levels of estradiol, which compete for estrogen receptors with PAHs 
from cigarette smoke (Mahabir et al. 2012).  
Boron has also therapeutic effects improving bone condition, wound healing and muscle 
differentiation. These will be treated in the following section, as they are of particular interest in 
this work.  
 
1.2.3. Boron in bone regeneration and maintenance 
Relevance of boron for osteogenesis was elucidated in studies that demonstrated that its 
deficiency adversely impacts bone development and regeneration. Chicks deprived from boron 
decreased their chondrocyte density in the growth plate (Hunt, Herbel, and Idso 1994), the 
second generation of frogs fed with low boron diet showed abnormal limb development (Fort et 
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al. 2000) and pigs fed with boron purified diet had lower bending moment, breaking load and 
tolerance stress on the femur (Armstrong et al. 2000). Rats fed on a low boron diet showed a 
significant lower femur strength, vertebral trabecular thickness and femur concentrations of 
copper, iron and magnesium compared to rats fed with 3mg/kg of boron (Nielsen, Stoecker, and 
Penland 2007; Nielsen and Stoecker 2009). In mice, dietary boron deprivation led to impaired 
modeling and remodeling of periodontal alveolar bone, since they had a 63%-48% reduction of 
osteoblast surface and 58%-73% increase in quiescent surface (Alejandro Gorustovich et al. 
2008b). The same group described how boron deprivation impaired bone healing, probably 
because of a reduction in the osteogenesis process (Alejandro Gorustovich et al. 2008a). 
Besides proving the adverse effects of low boron diets in animals, these studies have also 
shown how a boron supplement to the normal diet improved in overall bone strength. Of 
particular interest are the effects of boron in the regulation of key hormones and mineral 
metabolism, as it was mentioned in section 1.2.1. Boron supplementation in post-menopausal 
women reduced calcium and magnesium excretion in urine and increased serum levels of 17β-
estradiol and testosterone (Nielsen, Mullen, and Hunt 1987; Nielsen and Penland 1999). In this 
studies, as well as in others that show increase of sex hormones in serum (Naghii et al. 2011), it is 
suggested that it is unlikely that boron has a direct effect on mineral metabolism, because the 
amount of boron in the diet (3.25mg) was very low compared to the amount calcium, phosphorus 
and magnesium given (316-870mg). Instead, they suggest that boron regulates mineral 
metabolism through endocrine mechanisms, due to the significant increased levels of 17β-
estradiol and testosterone in serum, as well as the enhancement of the action of estrogen (Sheng 
et al. 2001) and vitamin D (Hunt, Herbel, and Idso 1994) on improving bone quality and mineral 
adsorption. 
 As described in Hunt et al. (1994), boron supplementation in chicks with inadequate 
intake of vitamin D alleviates the characteristic adverse effects of vitamin D deficiency. Miljkovic 
et al. (2004) proposed a mechanism through which boron could increase serum concentration of 
25-hydroxyvitamin D and improves its effects. His group suggested that boron suppresses the 
activity of 24-hydroxylase, a microsomal enzyme responsible for the catabolism of vitamin D, 
avoiding the degradation of the hormone. The same hypothesis applies to 17-β estradiol, which is 
catabolized too by a microsomal enzyme. Boron might do this by forming complexes with 
hydroxyl groups in cis orientation, which happen to be the end product of the hydroxylation of 
vitamin D and 17-β estradiol. The complex might act as a competitive inhibitor of the microsomal 
enzyme or as a down-regulator of the enzyme. Vitamin D affects bone health through diverse 
mechanisms (Sunyecz 2008). In vitamin D deficiency states, the absorption of calcium by the 
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intestine is decreased, causing increased osteoclast production. Osteoclasts break the bone 
matrix to release calcium and increase the amount of circulating calcium. Vitamin D directly 
interacts with receptors in the osteoblasts, increasing their formation. These osteoclasts also 
break the bone matrix. On the other hand, low serum calcium levels stimulate the parathyroid 
gland to release parathyroid hormone, which increases renal absorption of calcium and also 
osteoclast production. If vitamin D deficiency is not corrected, the bone matrix keeps being 
broken, leading to osteoporosis. Vitamin D deficiency has shown to damage bone, distort marrow 
sprouts, delay cartilage calcification, decrease calcium and phosphorus absorption, decrease 
growth and femur calcium concentration (Nielsen 2008). 
Regarding the reduction of calcium and magnesium excretion observed in boron 
supplemented diets, it is important to notice that 60% of human magnesium is found in bone, 
where it directly affects two regulators of calcium homeostasis: parathyroid hormone (PTH) and 
calcitriol, the active form of vitamin D. Hypomagnesemia results in an increase of intracellular 
calcium level, which inhibits the secretion of PTH, resulting in hypocalcemia, diminished 
reabsorption of calcium in kidney and low serum concentrations of vitamin D. Additionally, the 
enzyme responsible for production of calcitriol (the most active form of vitamin D), 25-
hydroxycholecalciferol-1-hydroxylase, requires magnesium as a cofactor. This results in 
hypomagnesemia impairing calcitriol production. Hypomagnesemia provokes also insulin 
resistance, altering the bone mineralization process by increasing glucose concentration, which 
has been shown to impair calcium deposition in bone. These findings, together with the 
regulation of hormone metabolism (vitamin D, estrogen and testosterone), explain how boron 
supplementation can improve bone regeneration and prevent bone loss in humans.  
However, more recent studies of the same group with higher sample numbers (Nielsen 
2004; Nielsen, Stoecker, and Penland 2007; Nielsen and Stoecker 2009) have shown that boron 
deprivation does not markedly affect calcium and phosphorus concentration in bone, but it 
affects the concentration of other mineral elements associated with the differentiation and 
activity of osteoblasts and osteoclasts, meaning that boron is directly beneficial for bone growth 
and maintenance by promoting osteoblasts activity and not through affecting bone calcium 
concentration or hormone homeostasis, even if its regulation may help to prevent bone loss. This 
provides more background to test how boron affects the in vitro differentiation of mesenchymal 
stem cells to osteoblasts. More support to this hypothesis is found in studies that have shown 
that boron upregulates the expression of genes related to tissue mineralization, osteoblastic 
differentiation and bone formation.  
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The effect of boron in pre-osteoblastic cells (MC3T3) (Hakki, Bozkurt, and Hakki 2010) and 
bone marrow stromal cells (BMSC) (Ying et al. 2011) was tested. The metalloid remarkably 
enhanced cell viability, proliferation, mineralization nodules and expression of bone mineralized 
tissue-associated proteins, particularly collagen type I, osteopontin, bone sialoprotein, 
osteocalcin, alkaline phosphatase and RunX2, compared to untreated cells. It also increased 
mRNA expression of bone morphogenetic protein (BMP), specifically BMP4, BMP5 and BMP7. 
BMP are growth factors that belong to the TGF-β family which induce formation of new cartilage 
and bone. RunX2 is a transcription factor that stimulates osteoblastic differentiation from 
mesenchymal stem cells, as well as bone formation and bone maintenance (Franceschi et al. 
2008). When its levels are reduced, other genes related to tissue mineralization drop its 
expression, as bone sialoprotein, osteocalcin and osteopontin. 
 Finally, several tissue engineering studies have shown beneficial effects of boron for 
osteoblast regeneration with different biomaterials. In 2003, Gough et al. tested the 
biocompatibility of PCL (polycaprolactone) and borontrifluoride for craniofacial bone 
regeneration. They showed improved cell proliferation, differentiation and higher amount of 
mineralized collagen 1 matrix in PCL scaffolds synthetized with borontrifluoride. Gorustovich et al. 
(2006) implanted bioactive glass particles modified with boron oxide in rat tibia. Boron increased 
bone regeneration, thickness and calcium:phosphorous ratio at 15 days. At 30 days post-
implantation, boron only improved thickness. They suggest that boron acts in an early stage of 
osteogenic differentiation. Wu et al. (2011) tested mesoporous bioactive glass scaffolds 
containing boron for the proliferation and differentiation of human osteoblasts. It was improved 
the expression of collagen I and RunX2 in the boron-containing scaffolds. These studies show and 
support the potential of boron in bone tissue engineering. 
 
1.2.4. Boron in myogenic differentiation 
In spite of all the evidence that supports the important role of boron in bone tissue 
regeneration, little is known about its effect on muscle tissue. Boron nitride nanotubes are being 
used as nanomaterials for biomedicine. However, this is mainly due to its physical-chemical 
characteristics, tridimensional structure and biocompatibility, not by a special improvement on 
muscle differentiation (Ciofani et al. 2013). It has been described how tetraphenylboron changes 
the charge of the surface of the sarcoplasmic reticulum, allowing Ca2+ release in skeletal muscle 
(Liu and Oba 1990; Soler, Fernandez-Belda, and Gomez-Fernandez 1989). However, the release of 
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Ca2+ is responsible for contraction of fully differentiated muscle cells, and does not have a paper in 
the differentiation. 
Only two recent studies have described the effects of boron in muscle differentiation. 
Apdik et al. (2015) tested the effect of boric acid on myogenic differentiation of human adipose 
stem cells (hADSC). Just 5μg/mL of boron increased cell viability and were not toxic for the cells. It 
increased expression of mRNA specific of myocytes in early stages of differentiation, particularly 
myosin heavy chain, myogenin, desmine and MyoD, being the last one the one with higher fold 
change compared to the control. However, a higher dose of boron at day 21 decreased the 
expression of these proteins.  
In the field of tissue engineering, Rico et al. (2015) showed the effect of poly-L-lactic acid 
(PLLA) substrates loaded with borax on the differentiation of murine C2C12 myoblasts, a model 
for muscle differentiation. The substrates containing borax had a higher percentage of 
differentiated cells and higher surface of myotube, compared to the standard control with 
collagen I as substrate. However, the myogenic markers MyoD and myogenin showed no 
significant improvement between the control and the PLLA substrates loaded with borax. This can 
be explained by the multistep process of differentiation of muscular cells, being possible that 
boron acts at an earlier stage than the moment when the analysis of the presence myogenic 
markers was done. 
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1.3. Biocompatible material: poly-L-lactic acid 
In tissue engineering, it is common the use of polymeric scaffolds or surfaces that serve as 
support and protection for the cells, having an environment similar to extracellular matrix of their 
native tissue (Langer and Vacanti 1993). The polymers can be used to induce differentiation of the 
cells ex vivo or can be implanted in vivo for tissue regeneration, with or without cells inside it.  
Ideal polymers for tissue engineering should be biocompatible and resorbable at a 
controlled rate which matches cell or tissue growth, should have a suitable chemistry for cell 
attachment, proliferation and differentiation, as well as mechanical properties to match those of 
the tissue to regenerate (Hutmacher 2000). Many polymers, natural or synthetic, have been used 
in tissue engineering. In this study poly-L-lactic acid (PLLA) has been chosen, as it can be 
considered as an ideal polymer, according to the characteristics mentioned above. It is composed 
by the L isomer of hydrophobic aliphatic polyester. PLLA has been widely approved by the US 
Food and Drug Administration (FDA) for direct contact with biological fluids and it is generally 
recognized as safe. 
As Farah et al. (2016) review, PLLA has numerous advantages compared to other 
biopolymers. PLLA’s production is eco-friendly, as it requires less energy to be produced -making 
it cheaper-, it is obtained from renewable sources and it is biodegradable. It is biocompatible and 
reabsorbable, meaning that its degradation products are not toxic and do not interfere with the 
tissue healing. In human body it is hydrolyzed to its constituent α-hydroxy acid, which is 
incorporated into the tricarboxylic acid cycle and excreted. It has higher processability, so it can 
be synthetized and shaped using multiple techniques. On the other hand, it has several 
drawbacks, as a slow degradation rate, low toughness and high hydrophobicity, which worsen cell 
affinity. However, these problems have been solved by blending PLLA with other polymers.  
PLLA has been widely used in biomedical applications that show its versatility: nerve and 
spinal cord injury regeneration, bioabsorbable screws in ankle, knee and hand; meniscus repair, 
guided bone regeneration, cardiac regeneration, stents, surgical sutures, dentistry, space filler, 
plastic and reconstructive surgery, dermal fillers, oncology, drug delivery, etc. (Tyler et al. 2016).  
It has been used both for bone and muscle regeneration, including in the Rico et al. ( 
2015) study with boron, were they prove that boron does not affect the properties of PLLA and 
analyzed its release from the polymer. It is then a suitable material to use as biocompatible 
substrate in this study. In this case it is not used as scaffold, because it has not been shaped as a 
tridimensional porous structure, but it is used as a surface easy to synthetize and that is simple to 
later analyze the cell differentiation, without requiring complex equipment.  
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1.4. Living cells: mesenchymal stem cells 
The key elements in tissue engineering are the living cells that are going to regenerate the 
damaged tissue. These cells can be derived from donor tissue or progenitor cells (Berthiaume, 
Maguire, and Yarmush 2011). The donor tissue can be from the patient or from other person, 
being the last one dangerous for the receptor due to immunological incompatibilities. Stem or 
progenitor cells have several advantages that make them suitable for tissue engineering: they 
have a high proliferative capacity and they are pluripotent (they can differentiate into several 
lineages). Stem cells can be obtained from embryos, placenta, umbilical cord, bone marrow of 
adults, or they can be induced pluripotent stem cells (iPSC), which can be any type of 
differentiated cell converted in stem cell.  
The cells chosen in this work are the murine embryonic mesenchymal stem cells 
C3H10T1/2. They have been demonstrated to differentiate into osteoblast, chondrocyte, 
adipocyte and myoblast, being suitable for this study (Shin et al. 2000). Mesenchymal stem cells 
(MSCs) have been used in tissue engineering (Ringe et al. 2002) due to their extensive in vitro 
proliferation and their potential to differentiate to multiple non hematopoietic lineages. 
MSCs can be differentiated to different lineages by adding specific inductors to culture 
medium. In this study, the lineages that are induced are osteoblast, myoblast and adipocyte. This 
last is used as a control for osteoblast differentiation, as bone induction blocks adipogenesis, and 
vice-versa (Q Chen et al. 2016). 
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2. Objective 
Myogenesis and osteogenesis are vital processes in the life cycle, which can be disrupted 
due to disease, injuries or aging. Tissue engineering aims at improving muscle and bone 
regeneration by using biomaterials, cells and biochemical factors that enhance genesis of tissue, 
to repair damages. Research and progress in developing and discovering any of the strategies of 
tissue engineering helps to this purpose.  
This study is motivated by the research done by our group in the Center for Biomaterials 
and Tissue Engineering (CBIT), where it is demonstrated that borax loaded PLLA substrates are 
able to induce muscle cell differentiation and myotube formation. Boron is a promising 
biochemical inducer, as it has demonstrated extensively its beneficial effects in life, health and 
muscle and bone differentiation, and hence regeneration. A step forward in the knowledge of 
how and under which circumstances does boron act can help to improve regenerative medicine. 
This work aims at testing the effect of boron in murine mesenchymal stem cells, 
particularly to demonstrate if it is capable to induce differentiation to osteoblast and myoblast 
lineages. This will allow knowing if boron acts at early stages of differentiation, before the 
compromise of cells to any particular lineage. The substrate used is poly-L-lactic acid prepared 
with a method in which PLLA merely acts as a support for the cells, being boron directly added to 
the culture medium. The study is qualitative, using fluorescence microscopy to analyze markers 
and morphology of the cells. 
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3. Materials and methods  
3.1. Experimental design  
This study is based on the qualitative analysis of the cells to check their differentiation 
state. The workflow is the following: 
1. Preparation of the polymeric substrates 
2. Preparation of cells and the different culture media 
3. Cell culture over the polymeric substrates 
4. Immunofluorescence essay and analysis with fluorescence microscopy OR 
staining and analysis with inverted optical microscope. 
5. Image treatment with specialized software 
A total of 4 different conditions are tested for each experiment, and there are a total of 9 
experiments.  
The four conditions are the following, each one with three samples:  
1. Crystal slide cover (C+, positive control) 
2. PLLA 
3. PLLA + 2% borax  
4. PLLA + 5% borax 
The nine experiments are defined by different molecular markers that define each type of 
cell (osteoblast, myoblast, adipocyte and stem cell undifferentiated). To each of the four 
conditions explained above, either basal medium (negative control) or differentiation medium are 
used.  
1. RunX2 (osteoblast) + basal medium 
2. RunX2 (osteoblast) + osteoblast medium 
3. OPN (osteoblast) + basal medium 
4. OPN (osteoblast) + osteoblast medium 
5. α-actinin (myoblast) + basal medium 
6. α-actinin (myoblast) + myoblast medium 
7. Liposome (adipocyte) + basal medium 
8. Liposome (adipocyte) + adipocyte medium 
9. Sca1 (stemness) + basal medium –> negative control 
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Given that, for each of the 9 experiments there are 4 conditions tested (positive control, 
PLLA, PLLA+2% borax, PLLA+5% borax), and for each condition there are 3 samples.  
 
3.2. Polymeric substrate 
The PLLA substrates were prepared from a solution of PLLA (Cargill Dow) dissolved in 100 
mL of chloroform to obtain a final concentration of 2% (w/v). The materials were prepared using 
spin coating technique. 
Spin coating is a method that allows to deposit a thin layer of the biopolymer (PLLA 2%) 
over a surface. The surfaces used were crystal slide covers of 12 mm diameter, with a total 
surface of 2 cm2. The slide covers are vacuum dried at room temperature in order to evaporate 
the excess of solvent. Boron is not released from the polymer, but it is added to the culture 
medium, with the same concentrations as if it was released from a solvent casting prepared 
polymer, as described by Rico et al. (2015): major release is produced during the first 3 hours of 
culture, and the release of borax increases as the concentration of borax in the sample does. At 
14 days there is still release of borax from the polymer. 
Two solutions of PLLA 2% containing 2% and 5% of borax (sodium tetraborate 
decahydrate Na2B4O7·10H2O) (Bórax España S.A) in relation to total mass of polymer were 
prepared, following the procedure of Rico et al. (2015). These will be added to the culture media 
depending on the experiment performed.  
 
The substrates were sterilized 30 minutes at UV light, before being used for cell culture. 
The two types of substrate were coated during 1h at room temperature with fibronectin 
(FN) from human plasma (Sigma-Aldrich), using a solution of 20 μg/mL in Dulbecco’s phosphate-
buffered saline (DPBS).  
 
3.3. Biological material and culture media  
The cells used were murine mesenchymal stem cells C3H10T1/2 (ATCC). They were 
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Invitrogen), supplemented with 10% 
fetal bovine serum (FBS; Invitrogen), 1% Fungizone (Life Technology, Fisher) and 1% penicillin–
streptomycin (Lonza) in humidiﬁed atmosphere at 37 ºC and 5% CO2. Cells were subcultured 
before reaching confluency, to obtain the needed concentration of cells before starting 
differentiation.  
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According to the nine experiments stated in section 3.1, it is necessary to use four 
different culture media.  It was added either 2% or 5% borax to the culture media, depending on 
the experiment performed.  
 Basal medium: DMEM + 10% FBS + 1% fungizone + 1% penicillin-streptomycin. 
o Borax 2% 
o Borax 5% 
 Osteogenesis induction medium: DMEM + 10% FBS + 1% fungizone + 1% 
penicillin-streptomycin + 50 μg/mL ascorbic acid + 10mM β-glycerophosphate + 
0.1 μM dexamethasone. 
o Borax 2% 
o Borax 5% 
 Myogenesis induction medium: DMEM + 10% horse serum (HS) + 1% fungizone + 
1% penicillin-streptomycin. 
o Borax 2% 
o Borax 5% 
 Adipogenesis induction medium: DMEM + 10% FBS + 1% penicillin-streptomycin + 
1% Fungizone + 0.5 mM, 3-isobutyl-1-methylxanthine + 60 μM Indometacine + 0.5 
μM Hydrocortisone 
o Borax 2% 
o Borax 5% 
Once obtained the desired concentration of cells, the cultures were stimulated to 
differentiate. 20000 cells/cm2 were cultured over FN-coated crystal slide cover (C+), PLLA, PLLA-
2% borax and PLLA-5% borax, three samples per each one of the substrates. The substrates of 
12mm Ø were placed in Nunclon plates of 24 wells. A total of 400 μL of culture media were 
added, according to the experiment (differentiation medium or basal medium; no borax, 2% 
borax or 5% borax). Every 3 days, the culture medium was changed. The cultures were kept in 
humidiﬁed atmosphere at 37 ºC and 5% CO2 until analysis of the samples was done. 
For OPN, α-actinin, adipogenesis and stemness experiments, the cultures were stopped at 
day 15. For RunX2, it was stopped at 3 days. For myoblast, osteoblast and stemness, the next step 
is an immunofluorescent essay. For adipocyte, it is a cell staining.  
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3.4. Immunofluorescence assay 
After the 3 or 15 days, depending on the experiment, the cultures were immunostained 
with specific markers of their lineage, in order to analyze their morphology and their stage of 
differentiation. 
The immunofluorescence assay is based in the binding of a primary antibody to the 
chosen molecular marker. Then, a fluorophore-conjugated secondary antibody is added. This 
binds to the primary antibody, and has fluorescence in a certain wavelength. Depending on the 
marker that wants to be seen, different primary and secondary antibodies are used.  
The general protocol for immunofluorescence begins fixing cells with formaline 4% and 
then permeabilizing the cells with DPBS/Triton X-100 0.5% during 5 minutes at room temperature. 
Next, cells are blocked during 1 hour at room temperature with DPBS and goat serum 5% (for 
RunX2, OPN and Sca1) or horse serum 5% for α-actinin sarcomeric. Cells are washed with 
DPBS/Triton X-100 0.1%.  
Cells are incubated with primary antibody 1 hour at 37 ºC or overnight at 4 ºC. The 
primary antibody is different depending on the marker:   
 Myoblast: mouse antibody anti mouse α-actinin sarcomeric (Abcam) dilution 
1:200 in DPBS/HS 5%. 
 Osteoblast: 
o Rabbit antibody anti mouse RunX2 (Abcam) dilution 1:200 in DPBS/GS 5%. 
o Mouse antibody anti mouse OPN (Santa Cruz Biotechnology) dilution 
1:200 in DPBS/GS 5%. 
 Stemness: rat antibody anti mouse Sca1 (Abcam) dilution 5μg/mL in DPBS/GS 5%. 
Unbound antibody is washed with DPBS/Triton X-100 0.1%.  
Cells are incubated with secondary antibody during 1 hour at 37 ºC. The secondary 
antibody is different depending on the primary antibody used. This is the antibody that gives the 
fluorescence, and depending on the fluorophore of the antibody, it will emit fluorescence in 
different wavelengths.  
 Myoblast: anti mouse Cy3 conjugated antibody (Jackson Immunoresearch) 
dilution 1:200 in DPBS/HS 5%. 
 Osteoblast: 
o Alexa Fluor 488 goat anti rabbit (Invitrogen) dilution 1:100 in DPBS/GS 5%. 
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o Alexa Fluor 488 goat anti mouse (Invitrogen) dilution 1:200 in DPBS/GS 
5%. 
 Stemness: Alexa Fluor 488 goat anti rat (Fisher) dilution 5μg/mL in DPBS/GS 5%. 
Unbound antibody is washed with DPBS/Triton X-100 0.1%.  
The samples are mounted in microscope slide covers, staining the nucleus with 
Vectashield containing DAPI (Atom) in the case of α-actinin sarcomeric, OPN and Sca1. For RunX2, 
it is mounted with FluorSave (Calbiochem WVR). 
The samples are observed under a fluorescence microscope (Nikon Eclipse 80i). 10 images 
for each condition (C+, PLLA, PLLA-B2%, PLLA-B5%) and experiment were taken. The channels 
were used according to the secondary antibody fluorophore: 
 α-actinin sarcomeric: DAPI channel (blue) and Cy3 channel (red). Images taken at 
10X and 20X magnification. 
 RunX2: Alexa Fluor 488 channel (green). Images taken at 20X and 40X 
magnification. 
 OPN: DAPI channel (blue) and Alexa Fluor 488 channel (green). Images taken at 
10X and 40X magnification. 
 Sca1: DAPI channel (blue) and Alexa Fluor 488 channel (green). Images taken at 
10X and 20X magnification. 
 
3.5. Cell staining 
After 15 days in adipocyte differentiation culture medium, the cultures are stained with 
Oil Red O, a fat soluble dye. Cells are equilibrated with isopropanol 60% during 2 minutes at room 
temperature. Oil Red O solution (1mg/mL Oil Red O (Sigma-Aldrich) + 60% isopropanol + distilled 
H2O) is added, 1mL per well, during 15 minutes at room temperature. Cells are washed twice with 
distilled water. The samples are mounted in microscope slide covers with glycerol. They are 
observed under inverted optical microscope. 10 images for each condition (C+, PLLA, PLLA-B2%, 
PLLA-B5%) and experiment were taken, at magnification 20X and 40X.  
 
3.6. Image treatment 
The obtained images were treated using the software Fiji (Image J), specialized for 
scientific image analysis. Images with high background noise were readjusted. The brightness and 
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contrast were adjusted in order to normalize all the images. As the images obtained from α-
actinin sarcomeric, Sca1 and OPN were separated in two channels, the nuclei and the cell, they 
were merged to have a complete vision of the cell morphology.  
It is important to notice that PLLA emitted green fluorescence, so in some cases the 
images had strong background noise.  
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4. Results and discussion 
4.1. Stemness 
As a negative control of differentiation, one experiment was a 15-day culture of 
mesenchymal stem cells in basal culture medium. This allow us to check how an undifferentiated 
cell should look under the four different conditions (C+, PLLA, PLLA+B2%, PLLA+B5%).  
The marker used for the immunofluorescence was Sca1 (stem cells antigen 1). It is a 
glycosyl phosphatidylinositol-anchored cell surface protein that is commonly used to identify 
mouse stem cells, including mesenchymal stem cells (Holmes and Stanford 2007). DAPI was used 
to stain the nucleus. 
Figure 1 shows the images of MSC cultured in basal medium, over crystal slide cover (C+) 
(A and B) and over PLLA (C and D). Under these conditions, the cells are undifferentiated and they 
cover most of the surface due to their continuous growth. In some cases, the cytoplasm of the 
cells can’t be discriminated due to overlapping between them.   
Figure 1. Immunofluorescence of Sca 1. Cell culture of MSC with basal medium. A and B) Culture over crystal 
slide cover, at 10X and 20X magnification respectively. C and D) Culture over PLLA, at 10X and 20X 
magnification respectively. 
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Figure 2 shows the images of MSC cultured over PLLA with basal medium, with 2% boron 
(A and B) and 5% boron (C and D). Cell density (according to the number of nuclei) does not 
decrease, supporting the theory that boron is not toxic for the cells. The marker Sca1 seems to be 
more expressed in these cells. No specific morphology can be observed in these cells, and 
probably they don’t acquire fibroblast-like shape due to the high cell density.  
 
Figure 2. Immunofluorescence of Sca 1. Cell culture of MSC with basal medium over PLLA. A and B) Culture in 
medium with 2% boron added, at 10X and 20X magnification respectively. C and D) Culture in medium with 
5% boron added, at 10X and 20X magnification respectively. 
 
4.2. Osteogenesis 
To test the cells for differentiation to the osteoblastic lineage, the markers used were 
RunX2 and OPN. 
RunX2 (runt-related transcription factor) is an essential transcription factor for osteoblast 
differentiation. It is detected in pre-osteoblasts, and its expression increases in immature 
osteoblasts (Komori 2010). As it is a transcription factor, it will be found in the nucleus when the 
cell is differentiating to osteoblast. In these experiments, the nucleus was not stained with DAPI, 
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so the RunX2 in the nucleus could be seen. 
OPN (osteopontin) is a soluble protein that is present intracellularly and as an 
extracellular structural protein that interacts with cell surface receptors, including integrins (Chen 
et al. 2014). It is expressed in immature osteoblasts rather in pre-osteoblasts, and it forms part of 
the extracellular matrix of bone (Komori 2010). The transcription factor RunX2 induces the 
expression of OPN. DAPI was used to stain the nucleus. 
 
4.2.1. RunX2 
These cultures were left during 3 days, presumably enough to induce early differentiation 
in mesenchymal stem cells. 
In figure 3 it is shown the culture of MSC over C+, with basal medium (A and B) and 
osteogenic medium (C and D). With basal medium the shape of the cells is similar to the shown in 
figures 1 and 2 of the Sca1 marker, meaning that the cells are undifferentiated. With 
differentiation medium, the shape changes to a more branched morphology.  
Figure 3. Immunofluorescence of RunX2. Cell culture of MSC over crystal slide cover. A and B) Culture with 
basal medium, at 20X and 40X magnification respectively. C and D) Culture with osteogenic medium, 20X 
and 40X magnification respectively. 
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In none of the cases, however, it is seen a clear location of the RunX2 marker inside the 
nucleus, where it should be in differentiated cells, so it must be located in the cytoplasm in its 
inactive form (non-phosphorylated). There exists the possibility that 3 days is a short time for 
osteoblast differentiation, as the bibliography reviewed used times of 1 week or longer. This 
means that the transcription factor is being synthetized but it is not being activated. 
 
In figure 4, cells cultured over PLLA substrate, with basal medium (A and B) and 
osteogenic medium (C and D) show in both cases a more branched morphology. In this case, in 
the C and D images it can be distinguished the fluorescence of the nuclei (red arrows), signaling 
the presence of the transcription factor RunX2 in the nucleus. Cell density in C and D is lower. It is 
possible that the PLLA substrate enhances cell differentiation under differentiation conditions.  
Figure 4. Immunofluorescence of RunX2. Cell culture of MSC over PLLA. A and B) Culture with basal medium, 
at 20X and 40X magnification respectively. C and D) Culture with osteogenic medium, 20X and 40X 
magnification respectively. 
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Figure 5 shows the cells cultured over PLLA substrate with boron 2% in the basal (A and B) 
and osteogenic (C and D) medium. In this case, it is evident the different morphology when 
comparing to the images in figure 2 (Sca1, PLLA+B2%), both in basal and osteogenic medium. The 
nuclei A and B have higher intensity compared to PLLA with basal medium, suggesting that boron 
can induce differentiation even with basal medium. Cell density in both cases is much lower than 
in the C+ and PLLA. Cell cycle is stopped during differentiation, so cells do not replicate. This 
means that a lower cell density is equal to higher differentiation. D and C figures show 
morphology more similar to osteoblast, as well as nuclei with a more intense fluorescence.  
Figure 5. Immunofluorescence of RunX2. Cell culture of MSC over PLLA with 2% boron in medium. A and B) 
Culture with basal medium, at 20X and 40X magnification respectively. C and D) Culture with osteogenic 
medium, 20X and 40X magnification respectively. 
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Figure 6 shows the cells cultured over PLLA substrate with boron 5% in the basal (A and B) 
and osteogenic (C and D) medium. These images show lower cell density comparing to PLLA+B2%, 
in basal and osteogenic medium. In both media the cells have a marked pre-osteoblast shape and 
defined nuclei. Additionally, in figures C and D the nuclei are clearly more intense, meaning that 
RunX2 is inside. When comparing these images to figure 3C and 3D (osteogenic medium in C+), 
and taking in account the nuclei intensity in figure 5, it is suggested that even if 3 days may be a 
short time for osteogenic differentiation, boron induces it, leading to the activation of RunX2.  
 
Figure 6. Immunofluorescence of RunX2. Cell culture of MSC over PLLA with 5% boron in medium. A and B) 
Culture with basal medium, at 20X and 40X magnification respectively. C and D) Culture with osteogenic 
medium, 20X and 40X magnification respectively. 
 
4.2.2. OPN 
These cultures were left during 15 days. Taking in account those 3 days could be few time 
to differentiate MSC to pre-osteoblasts, it is expected that 15 days are enough for immature 
osteoblasts, which is the stage when OPN is expressed. 
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In figure 7 it is shown the culture of MSC over C+, with basal medium (A and B) and 
osteogenic medium (C and D). The most noticeable difference between basal medium and 
osteogenic medium is how the cytoplasm is more delimited and there is less background in 
osteogenic medium. OPN has been found in MSC, being excreted to the medium, because it is 
used as signaling molecule too (Chen et al. 2014). However, it is upregulated in osteoblasts. It is 
possible that it is being synthetized and accumulated in the cytoplasm, and its excretion is 
performed later in the osteogenesis process.  
Figure 7. Immunofluorescence of OPN. Cell culture of MSC over crystal slide cover. A and B) Culture with 
basal medium, at 10X and 40X magnification respectively. C and D) Culture with osteogenic medium, 10X 
and 40X magnification respectively. 
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In figure 8, cells cultured over PLLA substrate, with basal medium (A and B) and 
osteogenic medium (C and D) show similar behavior that those of the cells cultured over C+ 
(figure 7). Cell density is very similar.  
 
Figure 8. Immunofluorescence of OPN. Cell culture of MSC over PLLA. A and B) Culture with basal medium, 
at 10X and 40X magnification respectively. C and D) Culture with osteogenic medium, 10X and 40X 
magnification respectively. 
 
Figure 9 shows the cells cultured over PLLA substrate with boron 2% in the basal (A and B) 
and osteogenic (C and D) medium. It can be seen the same result as with the other substrates: 
with osteogenic medium, the cytoplasm is more defined. Cell density seems lower in osteogenic 
medium, meaning that there are more differentiated cells compared to C+ in osteogenic medium 
(figure 7C and D). 
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Figure 9. Immunofluorescence of OPN. Cell culture of MSC over PLLA with 2% boron in medium. A and B) 
Culture with basal medium, at 10X and 40X magnification respectively. C and D) Culture with osteogenic 
medium, 10X and 40X magnification respectively. 
 
Figure 10 shows the cells cultured over PLLA substrate with boron 5% in the basal (A and 
B) and osteogenic (C and D) medium. In basal medium, cell density is very low, and cells have an 
amorphous shape. Cytoplasm is almost no defined. In some cells there is an intense fluorescence 
next to the nucleus. It is possible that 5% boron concentration is too high for this stage of 
differentiation and it is being counterproductive, particularly in the case of basal medium, as 
there is no other osteogenic inductor. In pictures C and D (osteogenic medium), the cytoplasm is 
more defined than in pictures A and B, but less than the cells with 2% boron. Cell density is low, 
signaling differentiation.  
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Figure 10. Immunofluorescence of OPN. Cell culture of MSC over PLLA with 5% boron in medium. A and B) 
Culture with basal medium, at 10X and 40X magnification respectively. C and D) Culture with osteogenic 
medium, 10X and 40X magnification respectively. 
 
4.3. Myogenesis 
The marker chosen for myogenesis was α-actinin sarcomeric. This is an actin-binding 
protein that is found in muscle. In skeletal muscle it is the major component of z-discs that define 
muscle sarcomeres, so it is expressed in developed myocytes. DAPI was used to stain the nucleus. 
In figure 11 it is shown the culture of MSC over C+, with basal medium (A and B) and 
myogenic medium (C and D). There is strong background and no definition of cytoplasm in A and 
B, showing the undifferentiated state of the cells. In myogenic medium (C and D), cells have an 
elongated shape, characteristic of myocytes and myoblasts. Cell density is much lower, meaning 
that there are differentiated cells. There are not, however, aligned cells that would indicate the 
formation of myotubes. It is possible that 15 days are not enough to obtain fully differentiated 
myoblast cells from mesenchymal stem cells. Rico et al. (2015) obtained myotubes in 4 days from 
the C2C12 myocyte cell line and Kubo (1991) obtained nucleated skeletal cells in two weeks from 
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C3H10T1/2 (the same cell line used in this work). However, both used different myogenic 
medium. It is possible that the chosen medium was not the suitable for this cell line. Another 
hypothesis is that the obtained cells are myocytes (an early stage of the myogenesis process) and 
not myoblasts, so α-actinin sarcomeric is less expressed and is not arranged in sarcomeres yet. 
Figure 11. Immunofluorescence of α-actinin sarcomeric. Cell culture of MSC over crystal slide cover. A and B) 
Culture with basal medium, at 10X and 20X magnification respectively. C and D) Culture with myogenic 
medium, 10X and 20X magnification respectively. 
 
Figure 12 depicts cells cultured over PLLA substrate, with basal medium (A and B) and 
myogenic medium (C and D). In basal medium, there is background and high density, same as in 
figure 11A and B. In C and D pictures, there is lower cell density and cells have lenticular shape, 
characteristic of myocytes. PLLA is possibly a substrate that enhances myogenesis, compared to 
slide covers.  
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Figure 12. Immunofluorescence of α-actinin sarcomeric. Cell culture of MSC over PLLA. A and B) Culture with 
basal medium, at 10X and 20X magnification respectively. C and D) Culture with myogenic medium, 10X and 
20X magnification respectively. 
 
Figure 13 shows the cells cultured over PLLA substrate with boron 2% in the basal (A and 
B) and myogenic (C and D) medium. In basal medium there is still high cell density and strong 
background. However, cells are more defined than in basal PLLA (fig 12A-B) and basal C+ (fig 11A-
B) and have an elongated shape. Cells in myogenic medium have the same lenticular shape as 
depicted in figure 12C-D. Cell density is lower, showing less proliferation and more differentiation.  
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Figure 13. Immunofluorescence of α-actinin sarcomeric. Cell culture of MSC over PLLA with boron 2% in 
medium. A and B) Culture with basal medium, at 10X and 20X magnification respectively. C and D) Culture 
with myogenic medium, 10X and 20X magnification respectively. 
 
Figure 14 shows the cells cultured over PLLA substrate with boron 5% in the basal (A and 
B) and myogenic (C and D) medium. There is less background and less cell density than cultures in 
boron 2%. Cell cytoplasm is also more defined compared to PLLA and C+ substrates. This means 
that boron might induce differentiation in basal medium. However, it is not clear the cell 
morphology and fluorescence is less intense than in the cultures without boron. An explanation 
can be that spontaneously and without other biochemical factor, boron induces differentiation to 
another cell line different from myoblast, probably to osteoblast. Pictures C and D show very low 
cell density, as indicator of differentiation. The morphology of the cell supports the theory that 
they are myocytes, and 5% of boron improves myogenesis when using myogenic medium.  
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Figure 14. Immunofluorescence of α-actinin sarcomeric. Cell culture of MSC over PLLA with boron 5% in 
medium. A and B) Culture with basal medium, at 10X and 20X magnification respectively. C and D) Culture 
with myogenic medium, 10X and 20X magnification respectively. 
 
4.4. Adipogenesis 
To test for adipogenic differentiation, an Oil Red O staining was performed. Oli Red O is a 
fat soluble dye which stains triglycerides and lipids in red. It makes visible the fats deposits in 
adipocytes. 
 
In figure 15 it is shown the culture of MSC over C+, with basal medium (A and B) and 
adipogenic medium (C and D). No red staining can be seen in basal medium, meaning there is not 
any adipocyte. By contrast, in adipogenic medium the stained fat vacuoles can be easily located. 
Cell density in the second case is low.  
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Figure 15. Staining of adipocytes. Cell culture of MSC over crystal slide cover. A and B) Culture with basal 
medium, at 20X and 40X magnification respectively. C and D) Culture with adipogenic medium, 20X and 40X 
magnification respectively. 
 
Figure 16 shows cells cultured over PLLA substrate, with basal medium (A and B) and 
adipogenic medium (C and D). Basal medium has no staining. In adipogenic medium, the amount 
of adipocytes is much higher than in C+. Possibly PLLA enhances adipogenesis.   
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Figure 16. Staining of adipocytes. Cell culture of MSC over PLLA. A and B) Culture with basal medium, at 20X 
and 40X magnification respectively. C and D) Culture with adipogenic medium, 20X and 40X magnification 
respectively. 
 
Figure 17 shows the cells cultured over PLLA substrate with boron 2% in the basal (A and 
B) and adipogenic (C and D) medium. In the basal medium, the cell density is slightly lower than in 
PLLA and C+ substrates without boron. There are no stained cells. In adipogenic medium, there 
are fewer adipocytes than in both PLLA and C+. Additionally, adipocyte morphology is atypical -
not rounded. They have a few ramifications and show a polygonal shape. Cell density is very low, 
depicting differentiation.  
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Figure 17. Staining of adipocytes. Cell culture of MSC over PLLA with 2% boron in medium. A and B) Culture 
with basal medium, at 20X and 40X magnification respectively. C and D) Culture with adipogenic medium, 
20X and 40X magnification respectively. 
 
Figure 18 shows the cells cultured over PLLA substrate with boron 5% in the basal (A and 
B) and adipogenic (C and D) medium. In A and B cell density is much lower compared to the other 
conditions with basal medium. Cell morphology is different from fibroblast, so possibly they are 
differentiated cells. Without the proper marker it can’t be confirmed, but the branched shape 
indicates that they can be pre-osteoblasts. C and D figures show even less adipocytes than 
PLLA+B2% (figure 17C-D). The few adipocytes have again a branched and polygonal shape, typical 
of pre-osteoblasts in culture.  
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Figure 18. Staining of adipocytes. Cell culture of MSC over PLLA with 2% boron in medium. A and B) Culture 
with basal medium, at 20X and 40X magnification respectively. C and D) Culture with adipogenic medium, 
20X and 40X magnification respectively. 
 
This provides more support to the hypothesis that boron inhibits the adipogenesis 
pathway by favoring osteogenesis. It is known that RunX2 blocks adipogenesis (Komori 2010). If 
boron activates RunX2, then it is consequent that in the presence of boron, adipogenesis is 
blocked. However, more experiments that lead to quantitative results are required. 
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5. Conclusions 
The objective of this research was to test the effect of boron on the differentiation of 
mesenchymal stem cells. The hypothesis, based on literature review, was that boron very 
probably induces osteogenesis, and possibly induces myogenesis. The mechanisms are unclear 
and it is not known at what stage of differentiation boron acts.  
 
The results shown here provide more insight on how boron induces cell differentiation. 
The analysis of the immunofluorescence assays of RunX2 suggest that boron acts at an early stage 
of differentiation, at 2% and 5% boron in culture medium. The morphology of the cells and the 
fluorescence in osteogenic medium in the positive control (slide cover) denote that 3-day time to 
induce osteogenesis is too short time. Even so, boron 5% was able to induce the expression of 
RunX2 and hence begin the process of osteogenesis.  When analyzing OPN immunofluorescence, 
it points out that boron 2% induces differentiation of osteoblasts, as the results are better than 
the positive control. However, in the culture with basal medium + boron 5% the cells do not 
produce OPN, and in osteogenic medium + boron 5% the grade of differentiation seems lower 
than that in positive control. This can mean that at 15-day, at later stages of osteogenesis, that 
concentration of boron is counterproductive for the osteoblast, as OPN is not produced in later 
immature osteoblasts.   
As negative control, the adipogenesis experiment showed how increasing concentrations 
of boron not only reduced adipogenesis, but also seemed to induce osteogenesis. If boron 
activates RunX2, then it is expected that adipogenesis is blocked, as the transcription factor 
avoids the expression of adipogenic inducer genes. Additionally, in basal medium, without any 
biochemical inducer, there can be seen cells with a pre-osteoblast morphology. Therefore, it can 
be concluded that boron induces osteogenesis, probably in early stages of the process, and 
probably activating RunX2, which is one of the first transcription factors to be activated in the 
differentiation of MSC. More experiments are needed to confirm this hypothesis. A quantitative 
experiment measuring level of expression of particular genes could be the most suitable choice. 
 
Myogenesis experiments are less concluding. The most plausible explanation is that the 
myogenic media was not correct for the used cell line, making the differentiation process slower 
than expected. Being the myogenesis slower is logical that cells differentiated to myocytes and 
not myoblasts (a more advanced stage). The marker chosen, α-actinin sarcomeric, gives the 
characteristic aligned shape of myotubes only when cells are fused myoblasts. As this was not the 
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case, the marker did not allow seeing the proper morphology of the cell, making difficult the 
analysis of the differentiation. Nevertheless, the lower cell density and the lenticular shape in B2% 
and B5% myogenic media show that to a certain extent boron might enhance myogenesis, but 
possibly in a more advanced stage of differentiation. More experiments need to be done to 
confirm this. 
It is interesting to notice the morphology of the cells and the cell density in B2% and B5% 
basal media of myogenesis experiment. Even if it is not a differentiation media, cells are 
differentiated to some lineage. As the marker chosen is for myogenesis, it can’t be certain what 
the lineage is. The same phenomena can be slightly observed in the Sca1 experiment: cells seem 
differentiated due to their shape in the culture. However, as the marker is for stemness, it is not 
clear which cell type might be. One hypothesis is that those cells are pre-osteoblasts, because 
boron shown in the adipogenesis and osteogenesis experiment that it can induce osteogenesis 
without any additional biochemical factor. To test this, it would be necessary to use other proper 
markers.  
The next step for this research is to confirm these results and test the hypothesis that 
boron induces osteogenesis without any additional factor and enhances myogenesis under 
particular conditions. The most reliable way to do this is to make a quantitave analysis of mRNA 
expression in the cells, to test the markers that represent various stages of differentiation of both 
lineages.  
 
The knowledge acquired in how boron acts and at what levels, makes tissue engineering 
to move one step forward, towards the obtaining of a new biochemical factor that will help in 
bone and muscle regeneration. As something to notice, PLLA enhanced in all cases cell 
differentiation, compared to slide covers. This reminds that the synergy between the biomaterial, 
the biochemical factor and the cells must be kept in order to improve tissue engineering as a 
whole, taking advantage of all of its sides to make every day this fascinating discipline a real 
application for biomedicine in the real world. 
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